Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
KOREA E & EX
Advantech Europe

Protection Device Minimizes Brain Damage in Cardiovascular Procedures

By HospiMedica International staff writers
Posted on 02 Oct 2013
Image: The TriGuard Cerebral Protection Device (Photo courtesy of Keystone Heart).
Image: The TriGuard Cerebral Protection Device (Photo courtesy of Keystone Heart).
An innovative cerebral protection device (CPD) reduces the volume of new brain lesions, especially during protected transcatheter aortic valve replacement (TAVR).

The TriGuard CPD is a Nitinol mesh embolic debris deflection device designed to cover all three aortic cerebral branches to minimize the risk of brain damage during cardiovascular (CV) procedures, and accommodates most anatomical variations of the aortic arch. The Nitinol frame and mesh are designed to be flexible and atraumatic, yet robust and sturdy, thus providing simple placement and retrieval.

The device is placed via one of two femoral artery access ports typically used in TAVR, eliminating the need for a third puncture site, and deploys rapidly, self-positioning through a 3-mm catheter. Studies have shown that compared with historical data on unprotected TAVR procedures, use of the TriGuard CPD decreased maximum total lesion volume by 95%, while average total lesion volume was 57% smaller, when compared with historical references. The TriGuard Cerebral Protection Device is a product of Keystone Heart (Caesarea, Israel), and has received the European community CE marking of approval.

“Cerebral function is the essence of quality of life. Its preservation throughout medical procedures is a key component to procedural success and patient care. TriGuard is the most sophisticated cerebral embolic protection device currently available,” said Andreas Baumbach, MD, consultant cardiologist at University Hospitals Bristol (United Kingdom). “The device has the potential to become a routine preventive measure in TAVR and other cardiovascular procedures associated with embolic lesions.”

Cerebral emboli are commonly associated with left-sided cardiac procedures. During CV procedures, debris from the aortic valve, ascending aorta, and other sources may embolize and cause cerebral infarction. Cerebral damage may not be clinically evident after CV procedures and can take months or years for symptoms to manifest, often as devastating stroke, dementia, and cognitive decline. Embolic brain lesions can be objectively and consistently detected by diffusion-weighted magnetic resonance imaging (DW-MRI).

Related Links:

Keystone Heart
University Hospitals Bristol



Channels

Critical Care

view channel

Transfusion Approach Reduces Death from Blood Loss

A new study shows that a blood transfusion with equal ratios of plasma, platelets, and red blood cells (RBCs) give patients a significantly better chance of survival. Researchers at the University of Maryland (College Park, USA), the University of Texas Health Science Center (Houston, USA), and other institutions conducted... Read more

Women's Health

view channel

Nitrous Oxide for Labor Makes US Comeback

Long used for its anxiolytic properties during labor in European countries and Canada, nitrous oxide (N2O) use is resurging in the United States. While in countries such as Norway, New Zealand, Sweden, Australia, and England, usage rates of inhalational N2O during parturition reach 70%, it has only recently become an... Read more

Health IT

view channel
Image: Remote Intelligent Telehealth Assistant (RITA) (Photo courtesy of PR Newswire).

Telehealth Robot Launched to Increase Productivity of Doctors in Clinics and Hospitals

A robot uses high-definition monitors, high-speed components, and wireless communications, and serves as a telehealth media center to give doctors more flexibility in treating and assisting patients remotely.... Read more

Business

view channel

Pfizer to Buy Hospira to Bolster Hospital Products

Pfizer (New York, NY, USA) has entered into a definitive merger agreement with Hospira (Lake Forest, IL, USA), in a move designed to significantly enhance their global established pharmaceutical (GEP) business, for a total enterprise value of approximately USD 17 billion. The strategic complementary combination will... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.